Skip to main content
. 2023 Mar 20;30(3):3494–3499. doi: 10.3390/curroncol30030265

Figure 1.

Figure 1

Tumor biopsy before ((A): adenocarcinoma) and after ((B): SCLC) progression to osimertinib.